Quick Answer
Protalix BioTherapeutics, Inc. reported Total Revenue of $52.74 million for fiscal year 2025.
Protalix BioTherapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $52.74M -1.2% |
$53.40M -18.5% |
$65.49M +37.5% |
$47.64M +24.2% |
$38.35M -39.0% |
$62.90M +15.0% |
| Net Income | -$6.60M -325.2% |
$2.93M -64.7% |
$8.31M +155.7% |
-$14.93M +45.9% |
-$27.58M -322.8% |
-$6.52M +64.3% |
| Diluted EPS | -$0.08 -300.0% |
$0.04 -55.6% |
$0.09 +129.0% |
-$0.31 +50.0% |
-$0.62 -181.8% |
-$0.22 +82.1% |
| Total Assets | $82.35M +12.2% |
$73.42M -13.0% |
$84.43M +51.4% |
$55.79M -24.3% |
$73.67M +8.4% |
$67.93M +49.7% |
| Cash and Equivalents | $14.68M -25.7% |
$19.76M -16.4% |
$23.63M +38.1% |
$17.11M -56.1% |
$38.98M +113.4% |
$18.27M +2.7% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $48.23M +11.6% |
$43.21M +28.7% |
$33.57M +415.5% |
-$10.64M -76.3% |
-$6.04M +77.7% |
-$27.04M +61.6% |
| R&D Expense | $19.57M +50.9% |
$12.97M -24.1% |
$17.09M -41.8% |
$29.35M -1.3% |
$29.73M -22.1% |
$38.17M -14.5% |
| Operating Income | -$5.50M -240.4% |
$3.92M -62.6% |
$10.46M +180.4% |
-$13.01M +36.4% |
-$20.46M -855.1% |
$2.71M +125.3% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 80.43M +6.0% |
75.85M +4.0% |
72.95M +35.6% |
53.79M +18.1% |
45.56M +31.0% |
34.77M +134.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $17.85M | -0.6% | +14.0% |
| Net Income | September 30, 2025 | $2.35M | -27.2% | +1336.0% |
| Diluted EPS | September 30, 2025 | $0.03 | +0.0% | — |
| Total Assets | September 30, 2025 | $82.26M | +33.6% | +4.8% |
| Cash and Equivalents | September 30, 2025 | $13.65M | -50.2% | -23.7% |
| Long-Term Debt | December 31, 2014 | $912.0K | -61.5% | -61.5% |
| Stockholders Equity | September 30, 2025 | $52.91M | +63.1% | +6.0% |
| R&D Expense | September 30, 2025 | $4.47M | +49.0% | -25.5% |
| Operating Income | September 30, 2025 | $2.13M | -46.6% | +81.8% |
| Gross Profit | September 30, 2018 | -$1.25M | -185.9% | -608.5% |
- Protalix BioTherapeutics, Inc. reported Total Revenue of $52.74 million for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed a decrease of -1.2% in Total Revenue compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Net Income of -$6.60 million for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed a decrease of -325.2% in Net Income compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Diluted EPS of $0.08 per share (loss) for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed a decrease of -300.0% in Diluted EPS compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Total Assets of $82.35 million for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed an increase of +12.2% in Total Assets compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Cash and Equivalents of $14.68 million for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed a decrease of -25.7% in Cash and Equivalents compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Long-Term Debt of $912.0 thousand for fiscal year 2014.
- Protalix BioTherapeutics, Inc. showed a decrease of -61.5% in Long-Term Debt compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Stockholders Equity of $48.23 million for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed an increase of +11.6% in Stockholders Equity compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported R&D Expense of $19.57 million for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed an increase of +50.9% in R&D Expense compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Operating Income of -$5.50 million for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed a decrease of -240.4% in Operating Income compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Gross Profit of $4.01 million for fiscal year 2017.
- Protalix BioTherapeutics, Inc. showed an increase of +400.7% in Gross Profit compared to the prior fiscal year.
- Protalix BioTherapeutics, Inc. reported Shares Outstanding of 80.43 million shares for fiscal year 2025.
- Protalix BioTherapeutics, Inc. showed an increase of +6.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: